Skip to main content

Table 2 Comparison of neurophysiological endpoints of acute oxaliplatin-induced motor nerve hyperexcitability

From: Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability

Number of Abnormal Tests/Total Number of Tests (%)

 

Spontaneous High Frequency Motor Unit Action Potentials

Repetitive Compound Motor Action Potentials

Before

Patients

0/8 (0%)

1/8 (13%)

Oxaliplatin

Muscles or Nerves

0/32 (0%)

1/32 (3.2%)

After Oxaliplatin

Patients

6/6 (100%)

5/7 (71%)

(Days 2-4)

Muscles or Nerves

16/22 (72%)

9/28 (32%)

After Oxaliplatin

Patients

2/8 (25%)

2/8 (25%)

(Days 14-20)

Muscles or Nerves

4/32 (12%)

3/31 (10%)

After Other

Patients

0/6 (0%)

1/6 (17%)

Platinum Drug

(Days 2-4)

Muscles or Nerves

0/24 (0%)

2/24 (8%)

Sensitivity*

Patients

100%

71%

 

Muscles or Nerves

72%

32%

Specificity*

Patients

100%

86%

 

Muscles or Nerves

100%

95%

  1. *For detecting oxaliplatin-induced motor nerve hyperexcitability on days 2 to 4 post-treatment